Localized paclitaxel delivery using a novel hyaluronic acid-coated fibrous carrier produced via needle-less electrospinning

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F46747885%3A24410%2F25%3A00013345" target="_blank" >RIV/46747885:24410/25:00013345 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1177/15280837251322712" target="_blank" >https://doi.org/10.1177/15280837251322712</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/15280837251322712" target="_blank" >10.1177/15280837251322712</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Localized paclitaxel delivery using a novel hyaluronic acid-coated fibrous carrier produced via needle-less electrospinning

Popis výsledku v původním jazyce

Pancreatic cancer remains one of the most challenging malignancies to treat due to its dense stromal microenvironment and resistance to conventional therapies. This study introduces a novel localized drug delivery system design to target residual cancer cells following surgery. Electrospun fibrous carriers were fabricated using needle-less electrospinning from polycaprolactone (PCL), silk fibroin (SF), and their blend. Among these, PCL carriers (average fiber diameter: 141 +/- 28 nm) exhibited the highest and most sustained paclitaxel (PTX) release in vitro. Coating the PCL carrier with hyaluronic acid (HA) increased the fiber diameter to 535 +/- 116 nm and modulated PTX release, shifting from an initial rapid release phase in uncoated carrier to a more gradual and sustained release over 120 hours. PTX-loaded HA-coated electrospun PCL carriers significantly reduced MiaPaCa cell viability, with only 13% viability at 96 hours compared to 22% for the non-coated carrier. This HA-coated electrospun PCL carrier offers a scalable and efficient solution for localized PTX delivery, providing sustained drug release, prolonged cytotoxic efficacy, and reduced off-target effects. Its industrial scaleability, combined with its potential for post-surgical pancreatic cancer management, presents an innovative approach to minimizing reliance on systemic chemotherapy and its associated toxicities. The use of needle-less NanospiderTM electrospinning technology further emphasizes its clinical potential, with future in vivo studies needed to confirm carrier‘s safety, pharmacokinetics, and therapeutic benefits.

Název v anglickém jazyce

Localized paclitaxel delivery using a novel hyaluronic acid-coated fibrous carrier produced via needle-less electrospinning

Popis výsledku anglicky

Pancreatic cancer remains one of the most challenging malignancies to treat due to its dense stromal microenvironment and resistance to conventional therapies. This study introduces a novel localized drug delivery system design to target residual cancer cells following surgery. Electrospun fibrous carriers were fabricated using needle-less electrospinning from polycaprolactone (PCL), silk fibroin (SF), and their blend. Among these, PCL carriers (average fiber diameter: 141 +/- 28 nm) exhibited the highest and most sustained paclitaxel (PTX) release in vitro. Coating the PCL carrier with hyaluronic acid (HA) increased the fiber diameter to 535 +/- 116 nm and modulated PTX release, shifting from an initial rapid release phase in uncoated carrier to a more gradual and sustained release over 120 hours. PTX-loaded HA-coated electrospun PCL carriers significantly reduced MiaPaCa cell viability, with only 13% viability at 96 hours compared to 22% for the non-coated carrier. This HA-coated electrospun PCL carrier offers a scalable and efficient solution for localized PTX delivery, providing sustained drug release, prolonged cytotoxic efficacy, and reduced off-target effects. Its industrial scaleability, combined with its potential for post-surgical pancreatic cancer management, presents an innovative approach to minimizing reliance on systemic chemotherapy and its associated toxicities. The use of needle-less NanospiderTM electrospinning technology further emphasizes its clinical potential, with future in vivo studies needed to confirm carrier‘s safety, pharmacokinetics, and therapeutic benefits.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20503 - Textiles; including synthetic dyes, colours, fibres (nanoscale materials to be 2.10; biomaterials to be 2.9)

Projekt

<a href="/cs/project/EF16_019%2F0000843" target="_blank" >EF16_019/0000843: Hybridní materiály pro hierarchické struktury</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JOURNAL OF INDUSTRIAL TEXTILES

ISSN

1528-0837

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

FEB

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

27

Strana od-do

1-27

Kód UT WoS článku

001427575500001

EID výsledku v databázi Scopus

—